The Prevention through Risk Identification, Management, and Education (PRIME) study, funded by the National Institute of Mental Health and Eli Lilly, tested the hypothesis that olanzapine might prevent the onset of psychosis in people at very high risk for schizophrenia.
The Prevention through Risk Identification, Management, and Education (PRIME)-studien, finansierad av National Institute of Mental Health och Eli Lilly, testade hypotesen att Ooanzapin kan förhindra start av psykos hos personer med mycket hög risk för schizofreni.